Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18471225 | 0.80 | SMN1; SMN2 (0.49) | PARP1TSHRCYP3A4SMN1; SMN2POLB | |
| SCHEMBL10831613 | 0.80 | PARP1 (0.46) | PARP1TSHRCYP3A4SMN1; SMN2POLB | |
| SCHEMBL3220166 | 0.78 | CA1 (0.48) | PARP1TSHRCYP3A4SMN1; SMN2MAPT | |
| SCHEMBL1004660 | 0.78 | PARP1 (0.50) | PARP1TSHRCYP3A4SMN1; SMN2POLB | |
| SCHEMBL16384671 | 0.78 | TPMT (0.58) | TSHRSMN1; SMN2MAPTHSD17B10TDP1 | |
| SCHEMBL16769478 | 0.78 | CA5A (0.48) | SMN1; SMN2MAPTTDP1L3MBTL1LMNA | |
| SCHEMBL1397262 | 0.78 | POLB (0.50) | PARP1TSHRCYP3A4SMN1; SMN2POLB | |
| SCHEMBL1003411 | 0.76 | PARP1 (0.43) | PARP1TSHRCYP3A4SMN1; SMN2POLB | |
| SCHEMBL1002938 | 0.76 | CYP3A4 (0.48) | PARP1TSHRCYP3A4SMN1; SMN2POLB | |
| SCHEMBL16384672 | 0.76 | TPMT (0.34) | TSHRSMN1; SMN2MAPTTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | claimed |
| CN-107847600-B | Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3302549-B1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3302549-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-2362868-B1 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | disclosed |
| CN-107382781-A | The preparation method of L alanine derivatives through protection | 詹森药业有限公司 | 2017-11-24 | — | — | CN | disclosed |
| US-9657351-B2 | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist | HOFFMAN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| CN-102264691-B | Process for the preparation of protected l-alanine derivatives | 詹森药业有限公司 | 2017-05-03 | — | — | CN | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-8853445-B2 | Process for the preparation of protected L-alanine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-10-07 | — | — | US | disclosed |
| US-20140135525-A1 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-05-15 | — | — | US | disclosed |
| US-8710256-B2 | Process for the preparation of protected L-alanine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-04-29 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100145090-A1 | PROCESS FOR THE PREPARATION OF PROTECTED L ALANINE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135525-A1 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | OPRD1, OPRM1, OPRK1 | PARP1 3921/4885TSHR 3338/4885BPTF 4787/4885 |
| US-20100145090-A1 | PROCESS FOR THE PREPARATION OF PROTECTED L ALANINE DERIVATIVES | OPRD1, OPRM1, OPRK1 | PARP1 4077/4885TSHR 3252/4885BPTF 4782/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | PARP1 25/4885TSHR 846/4885BPTF 3502/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | PARP1 25/4885TSHR 846/4885BPTF 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.